Results 111 to 120 of about 111,593 (328)
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source
Glycyrrhizic Acid Reduces Heart Rate and Blood Pressure by a Dual Mechanism [PDF]
, 2016 published_or_final_versio
Chow, BKC, Sekar, R, SINGH, K, ZAW, AM
core +1 more source
ESC Heart Failure, EarlyView.Abstract Chronic kidney disease (CKD) and chronic heart failure (HF) frequently coexist and, when comorbid, are associated with poorer outcomes. These two diseases have common risk factors, such as diabetes, obesity and hypertension, and common pathophysiological connected mechanisms, including inflammation, endothelial dysfunction, neurohormonal ...
Johann Bauersachs +2 more
wiley +1 more source
Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics. [PDF]
, 2019 Mood disorders are highly prevalent and are the leading cause of disability worldwide. The neurobiological mechanisms underlying depression remain poorly understood, although theories regarding dysfunction within various neurotransmitter systems have ...
Dulawa, Stephanie C, Janowsky, David S
core
Alpha- and beta-adrenergic mediation of changes in metabolism and Na/K exchange in rat brown fat [PDF]
, 1985 Double- and triple-barreled ion-sensitive microelectrodes were used to measure changes in extracellular K+ and Na+ concentrations ([K+]o, [Na+]o) in brown fat.
Coles, Jonathan A. +2 more
core +2 more sources
European Journal of Heart Failure, EarlyView.Abstract A better understanding of additional mechanisms of heart failure (HF) progression may allow a different and more complete phenotyping of the disease and identification of novel therapeutic targets. Persistent latent myocardial inflammation/immune activation in HF may represent an attempt to restore tissue homeostasis in the failing heart ...
Gabriele Fragasso +20 more
wiley +1 more source
Concentration‐effect relationships with FM 24: a new long acting beta‐ adrenergic receptor antagonist. [PDF]
, 1983 C. T. Dollery +3 more
openalex +1 more source
The Postural Tachycardia Syndrome (POTS): Pathophysiology, Diagnosis & Management [PDF]
, 2006 Postural tachycardia syndrome (POTS), characterized by orthostatic tachycardia in the absence of orthostatic hypotension, has been the focus of increasing clinical interest over the last 15 years 1. Patients with POTS complain of symptoms of tachycardia,
Raj, Satish R
core +1 more source
The Journal of Clinical Pharmacology, EarlyView.Abstract Impaired awareness of hypoglycemia (IAH) impacts 25%–30% of individuals with type 1 diabetes mellitus (T1D), potentially leading to severe outcomes due to reduced symptom perception. Naloxone, a mu‐opioid receptor antagonist, shows promise as a preventive measure against IAH.
Omar N. Al Yacoub +9 more
wiley +1 more source
Vitae, 2014 Background: Cardiovascular and respiratory effects of adrenergic agonists used in diseases like chronic obstructive pulmonary disease (COPD), and β-blockers used in glaucoma generate competitive antagonism on the same adrenergic receptor when used ...
Jorge Enrique Machado-Alba +1 more
doaj